Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ny developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - SQI Diagnostics ... life sciences company that develops and commercializes proprietary technologies ... financial and operational results for the second fiscal quarter ... quarter the Company continued to advance business with our ... Andrew Morris , President and CEO of SQI. "The ...
(Date:5/21/2015)... 21, 2015  Prima Biomed Ltd. (NASDAQ: PBMD ... to become a leader in the development of immunotherapeutic ... the final CVac data from the Phase II CAN-003 ... for a clinically meaningful improvement in Overall Survival ("OS") ... In the group of second remission patients ...
(Date:5/21/2015)... 2015 W. R. Grace & ... in Worms, Germany has received good manufacturing practice ... the International Pharmaceutical Excipient Council (IPEC) Foundation. ... its SYLOID® FP brand of pharmaceutical grade excipient ... the Curtis Bay, Maryland (USA) and Sorocaba, Brazil ...
(Date:5/21/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ) ... Global Survey on Flow Cytometry Adoption Trends" ... goal of this research is to analyze the ... information the survey seeks to collect include factors ... used applications for flow cytometers, respondents, most preferred ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Correction Continues after Big Move - BrokerBank Securities, Inc. 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Global Survey on Flow Cytometry Adoption Trends 2015 2
... 29 Core Informatics announces,that it has delivered ... BioRelix Pharmaceuticals of New Haven, CT. BioRelix, which ... to establish a,strong data management infrastructure from the ... marketplace, BioRelix choose the Core LIMS., "After ...
... REDWOOD CITY, Calif., April 29 Genomic,Health, Inc. (Nasdaq: ... call and webcast on Tuesday, May 6, 2008 at 4:30 ... The call and,webcast will follow the release of the first ... To access the live conference call on May 6 at ...
... the,international life sciences investment group, today announced the,appointment ... based at the Company,s,offices in Waltham, MA, USA ... efforts in growth equity, which will include expansion ... and life,science companies. Abingworth plans to invest from ...
Cached Biology Technology:Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals 2Genomic Health to Announce First Quarter 2008 Financial Results and Host Conference Call on Tuesday, May 6, 2008 2Abingworth Appoints David Mayer as Partner 2
(Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... a well-rounded UAS delegation representing private industry, government, and academia, ... AUVSI,s Unmanned 2015 conference last week in Atlanta ... UAS industry met with over 200 hundred people from companies ... ecosystem. "Our message is clear and consistent," ... Rich Knoll . "If you want to fly UAS, you ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... Laboratory, San Diego, California, has been awarded an ... based on results of a recent onsite inspection. ... of this national recognition and congratulated for the ... Inc. GenWay Clinical Laboratory is one of nearly ...
... release is available in German . Despite the ... cultures vary as to how space is encoded in their language. ... right, front, back, to talk about spatial relations, instead using allocentric ... scales: "The spoon is north of the bowl" or "There is ...
... consumers can look forward to ultra-low powered or self ... phones. This is made possible with power management and ... power optimisation and higher energy efficiency in electronic devices ... enabling capability for power management and energy harvesting. To ...
Cached Biology News:More than a jump to the left 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3
... Acid) Clear to very pale yellow ... 2 O 2 in a citrate buffer ... is soluble, safe, convenient and has good overall ... blue-green color that can be measured at 405 ...
...
... new IKATUBE ULTRA TURRAX Tube Disperser System from ... system. It offers a cleaner, safer, and more ... processes sample volumes from 2 to 15 ml ... researchers can choose one of 4 different tube ...
...
Biology Products: